Read More Pharma Industry News Gilead’s CAR T breakthrough: Yescarta delivers consistent results beyond transplant settings Yescarta shows durable survival and response benefits in second-line large B-cell lymphoma across transplant-eligible and ineligible patients. Read the latest trial update. byPallavi MadhirajuDecember 8, 2025